FitLine:

Product

Quality

vs.

Business

Model

—

Two

Different

Questions

Suppose we removed the FitLine name.

Suppose we also removed the distributor, the compensation plan and the entire network-marketing structure.

A supplement would still leave us with familiar questions:

• What's in it?
• At what dose?
• In what form?
• How is it manufactured?
• How is it tested?
• What evidence supports the claimed effects?
• What does it cost?

Those are product questions.

We've already looked at several of them in this investigation — ingredients, manufacturing, testing, bioavailability and the difference between mechanistic and clinical evidence.

None of those questions requires us to know how a salesperson gets paid.

A vitamin doesn't become better because it is sold in a supermarket.

And it doesn't become worse because it is sold through a distributor.

The product has to stand on its own evidence.

Let's run the experiment in the opposite direction.

Imagine we knew nothing about the ingredients.

Instead, we're offered a business opportunity.

Now the relevant questions change:

• What do I have to do to qualify for commissions?
• Can I make money from genuine retail sales?
• Do I need to recruit other participants?
• Are recurring purchases required or economically encouraged?
• What expenses am I likely to incur?
• What do typical participants earn?

Those are business-model questions.

Knowing that the product was manufactured under GMP conditions doesn't answer them.

Neither does a positive clinical study.

A perfectly manufactured product cannot turn gross commissions into net profit.

Discussions about network marketing tend to collapse two investigations into one.

One side says:

“MLM = bad product.”

The other says:

“I use the product and love it = good business.”

Neither conclusion follows automatically.

Someone can genuinely like a product and lose money trying to sell it.

Someone can dislike the distribution model while the product itself meets legitimate manufacturing standards.

And a company can have satisfied customers without every health claim being equally well supported.

These aren't contradictions.

They're different questions.

This distinction becomes easier if we stop asking whether a company is simply “good” or “bad.”

Ask four narrower questions instead.

1 — Product QualityLook for:LabelFormulationManufacturingQuality controlTestingThis tells us whether the product appears to be made under a credible quality system.It doesn't prove clinical effectiveness.

2 — Product EvidenceLook for:ClaimStudyProductDosePopulationOutcomeThis tells us how far the scientific evidence supports the claim.It doesn't tell us whether the product is good value.

3 — Customer ValueNow ask:PriceDoseAlternativesConvenienceCustomer prioritiesTwo equally well-made products can offer very different value.And value is partly contextual.Convenience may matter.Taste may matter.A bundled system may matter.Price certainly matters.

4 — Business OpportunityFinally:Retail demandCompensationQualificationExpensesTypical earningsNet resultThis requires an entirely different evidence set.

Network marketing introduces an unusual overlap.

The same person can be:

a customeranda distributor

That isn't automatically a problem.

FTC guidance recognizes that participant purchases can reflect genuine personal consumption. The important issue is not simply whether distributors buy products themselves, but how the compensation structure operates in practice and what incentives it creates.

For example, regular purchases become more relevant to the business-model analysis if participants are encouraged to buy quantities they don't genuinely want or need in order to remain eligible for rewards.

So a useful distinction is:

Would I buy this because I want the product?versusAm I buying this because I need the volume?

The transaction may look identical.

The economic reason behind it isn't.

Sources: FTC — Business Guidance Concerning Multi-Level Marketing (independent / regulatory guidance)

Here's a useful thought experiment.

Would people still buy the product if there were no business opportunity attached to it?

If the answer is yes, that's evidence of genuine consumer demand.

It doesn't prove the product's scientific claims.

It doesn't prove that its price is competitive.

But it tells us something important about the market:

the product has a reason to exist beyond recruitment.

Repeat purchases can strengthen that signal.

Again, carefully:

People repeatedly buy plenty of things for reasons other than measurable health outcomes.

But repeat purchasing by genuine end customers is still commercially different from product volume generated primarily because participants need to qualify for compensation.

That distinction matters when examining a network-marketing system.

Now reverse the question.

Would someone still join the business if they were shown the typical net financial outcome before joining?

This is harder to answer.

And this is exactly why earnings evidence matters.

A distributor might receive $5,000 in commissions during a year.

That sounds like income.

But suppose operating the business required:

• product purchases
• samples
• shipping
• travel
• events
• subscriptions
• advertising
• websites
• training
• or other expenses

Then $5,000 isn't necessarily $5,000 of profit.

REVENUE + COMMISSIONS− BUSINESS EXPENSES= NET RESULT

FTC guidance says participant expenses have to be considered when evaluating earnings representations.

That's not an anti-MLM standard.

It's ordinary business accounting.

Sources: FTC — Business Guidance Concerning Multi-Level Marketing (independent / regulatory guidance)

Successful distributors exist.

Their success is real.

But it answers a different question:

Can someone achieve this result?

A prospective distributor usually needs the answer to:

What result is typical?

Those aren't interchangeable.

The FTC's 2024 staff review examined publicly available income disclosures from 70 MLM companies.

That is an industry-level finding, not a FitLine finding.

It would be wrong to simply transfer that number to PM-International.

Instead, it tells us what evidence we need when we investigate PM-International specifically.

We need its numbers.

Sources: FTC Staff Report, September 2024 — Multi-Level Marketing Income Disclosure Statements (independent / regulatory research)

This is where our FitLine investigation becomes useful.

We've already found evidence relevant to several product-side questions.

FitLine provides identifiable product labels and formulations.

We've examined manufacturing and GMP.

We've looked at external testing and the Cologne List.

We've examined NTC-related research and separated laboratory uptake evidence from human clinical evidence.

None of that disappears because FitLine is sold through network marketing.

But none of it establishes the business opportunity either.

For that, we need a different investigation:

• PM-International's current compensation plan.
• Qualification requirements.
• Customer sales.
• Distributor purchasing.
• Bonuses.
• Expenses.
• And — if sufficiently transparent data exist — the distribution of actual participant earnings.

Only then can we say something useful about the opportunity itself.

This distinction deserves particular care.

Multi-level marketing describes a distribution and compensation structure.

An illegal pyramid scheme is a legal and economic determination that depends on how the structure actually operates.

FTC guidance says this assessment is fact-specific.

Among the things it examines are marketing representations, participant experiences, the compensation plan and the incentives the plan creates — including whether incentives favor recruitment or product sales to genuine end users.

So InfoDrops shouldn't look at a compensation diagram and casually declare:

“Pyramid scheme.”

But neither should the existence of real products end the investigation.

The relevant question is:

That's an evidence question.

And we'll treat it like one.

Sources: FTC — Business Guidance Concerning Multi-Level Marketing (independent / regulatory guidance)